Target Price | $32.14 |
Price | $30.27 |
Potential |
6.19%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target CEVA 2025 .
The average CEVA target price is $32.14.
This is
6.19%
register free of charge
$40.00
32.14%
register free of charge
$21.00
30.62%
register free of charge
|
|
A rating was issued by 7 analysts: 6 Analysts recommend CEVA to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the CEVA stock has an average upside potential 2025 of
6.19%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 97.42 | 105.07 |
27.65% | 7.85% | |
Net Margin | -12.37% | -7.98% |
29.51% | 35.49% |
6 Analysts have issued a sales forecast CEVA 2024 . The average CEVA sales estimate is
This results in the following potential growth metrics:
2 CEVA Analysts have issued a net profit forecast 2024. The average CEVA net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.51 | -0.36 |
49.00% | 29.41% | |
P/E | negative | |
EV/Sales | 5.35 |
2 Analysts have issued a CEVA forecast for earnings per share. The average CEVA <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the CEVA stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.